- Home
- PIII vs ANTX Comparison
PIII vs ANTX Comparison
Compare PIII & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- ANTX
- Stock Information
- Founded
- PIII 2015
- ANTX 2017
- Country
- PIII United States
- ANTX United States
- Employees
- PIII N/A
- ANTX N/A
- Industry
- PIII Medical/Nursing Services
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- ANTX Health Care
- Exchange
- PIII Nasdaq
- ANTX Nasdaq
- Market Cap
- PIII 32.2M
- ANTX 37.6M
- IPO Year
- PIII N/A
- ANTX 2022
- Fundamental
- Price
- PIII $0.19
- ANTX $1.26
- Analyst Decision
- PIII Buy
- ANTX Hold
- Analyst Count
- PIII 3
- ANTX 5
- Target Price
- PIII $2.38
- ANTX $3.50
- AVG Volume (30 Days)
- PIII 5.4M
- ANTX 133.1K
- Earning Date
- PIII 11-12-2024
- ANTX 11-13-2024
- Dividend Yield
- PIII N/A
- ANTX N/A
- EPS Growth
- PIII N/A
- ANTX N/A
- EPS
- PIII N/A
- ANTX N/A
- Revenue
- PIII $1,476,630,000.00
- ANTX N/A
- Revenue This Year
- PIII $21.45
- ANTX N/A
- Revenue Next Year
- PIII N/A
- ANTX N/A
- P/E Ratio
- PIII N/A
- ANTX N/A
- Revenue Growth
- PIII 25.38
- ANTX N/A
- 52 Week Low
- PIII $0.18
- ANTX $0.87
- 52 Week High
- PIII $1.35
- ANTX $21.40
- Technical
- Relative Strength Index (RSI)
- PIII 39.59
- ANTX 43.51
- Support Level
- PIII $0.19
- ANTX $1.34
- Resistance Level
- PIII $0.29
- ANTX $1.28
- Average True Range (ATR)
- PIII 0.03
- ANTX 0.06
- MACD
- PIII -0.00
- ANTX -0.01
- Stochastic Oscillator
- PIII 4.30
- ANTX 18.18
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.